Background {#Sec1}
==========

Pneumothorax is a relatively common complication in newborns infants (6--10% in very low birth weight preterm infants and around 1% in term infants \[[@CR1]\]), especially when receiving invasive mechanical ventilation, but also during non-invasive ventilatory support such as continuous positive airways pressure (CPAP) \[[@CR2]\]. A 40% increase of FiO~2~ during the first 24 h of CPAP has been suggested as a useful marker to identify the infants at high risk of developing a pneumothorax \[[@CR3]\]. Recently successful management strategies have been reported of symptomatic pneumothorax diagnosed in preterm infants receiving assisted ventilation, which avoided chest tube drainage and resulted in reduction of important side effects \[[@CR4], [@CR5]\]. In this case series, we reported our experience of using high-frequency oscillatory ventilation (HFOV) as a first-line treatment of pneumothorax in preterm infants with respiratory distress syndrome.

Cases presentation {#Sec2}
==================

We report the experience of five neonates (4 males and 1 female), with mean ± SD birth weight of 1211 ± 40 g and mean ± SD gestational age of 30 ± 2 weeks. All infants were delivered by caesarean section due to preeclampsia (one case), gestational hepatosis and preeclampsia (one case), preterm labor (one case), growth restriction (one case) and ascites of the second twin (one case); three of them were twin-birth. Premature rupture of membranes did not occur in any of the cases. All the mothers received at least one dose of betamethasone. Soon after birth, all the infants developed respiratory distress (Silverman score 3--4) and were placed on a ventilator nasal CPAP system with a pressure level of 4--6 cmH~2~O and a FiO~2~ of 0.25--0.30 for a diagnosis of respiratory distress syndrome based also on the typical chest X-ray. CPAP failure criteria (FiO~2~ ≥ 0.40) was reached in two cases (patient 3 and 5), and surfactant was administered (200 mg/kg of poractant alfa, Chiesi Farmaceutici, Italy) with the INtubation-SURfactant-Extubation (INSURE) approach respectively at 9 h and 6 h of life.

On median \[range\] postnatal day 3 \[2--4\] respiratory distress (quantified by means of Silverman score) worsened, with a concomitant increase of respiratory rate, of capillary P~CO2~ values and of FiO~2~ to obtain SpO~2~ values 90--95% (Table [1](#Tab1){ref-type="table"}). Chest X-rays showed the presence of pneumothorax on the right side in two patients and on the left side in the other three ones. Heart rate and blood pressure remained within normal range for the gestational age. All 5 neonates were intubated and mechanically ventilated using HFOV delivered by a BabyLog 8000 plus ventilator (Dräger, Lubeck, Germany) in the first 4 cases and by a BabyLog VN500 (Dräger, Lubeck, Germany) in the 5th case (Table [1](#Tab1){ref-type="table"}). Ventilation was started with a median \[range\] mean airways pressure (MAP) of 8 \[8-9\] cmH~2~O, amplitude of 100% in the first 4 cases and ΔP of 15 cm H~2~O in the last case ventilated with Baby-log VN500, frequency of 10 Hz. The oscillation amplitude with the BabyLog 8000 plus is adjustable as a percentage from 0 to 100%, where 100% means the highest possible amplitude under the given circumstances of MAP and frequency settings as well as the characteristics of the respiratory system. In the first 4 cases receiving HFOV by BabyLog 8000 plus, amplitude was gradually increased up to 100% until the infant's chest was seen to be "visibly vibrating", providing the MAP as low as possible for the presence of air leak. All the newborns received Remifentanil by continuous intravenous infusion at a dose of 0.075 μg/kg/min to provide analgesia and sedation during HFOV \[[@CR6]\]. Despite the start of mechanical ventilation, the FiO~2~ requirement remained quite high (0.50--0.60) in two cases (patients 2 and 3) and these neonates received 1 dose of surfactant (Table [1](#Tab1){ref-type="table"}). In two patients, a diagnosis of pneumonia was made afterwards, based on the results of bronchoalveolar lavage fluid culture positive for *Candida spp.* (patient3) and for *Group B Streptococcus* (patient 4) (Table [1](#Tab1){ref-type="table"}). In all the five cases, the infants' oxygen requirement and ventilatory support gradually decreased during the subsequent days. Chest X-rays showed a progressive and complete resolution of the pneumothorax within 48--96 h (Fig. [1](#Fig1){ref-type="fig"}). All the infants were successfully extubated with a median \[range\] MAP of 6 \[5.5--6\] cmH~2~O, amplitude of 100 \[25--100\] % in the first 4 cases and ΔP of 15 cm H~2~O in the last case, frequency of 8 \[7-10\] Hz and FiO~2~ of 0.23 \[0.21--0.25\]. All infants survived with normal head ultrasounds and without bronchopulmonary dysplasia, defined as oxygen requirements or need of ventilatory support at 36 weeks of post menstrual age.Table 1Patients characteristics, pneumothorax details, respiratory status prior to intubation and starting ventilatory parametersCPatient 1Patient 2Patient 3Patient 4Patient 5Gestational Age (weeks)31^+6^30^+2^27^+5^33^+2^28^+5^SexMaleMaleFemaleMaleMaleBirth Weight (g)12401215120512501145DeliveryCaesarean sectionCaesarean sectionCaesarean sectionCaesarean sectionCaesarean sectionRespiratory DiagnosisRespiratory Distress SyndromeRespiratory Distress SyndromeRespiratory Distress Syndrome; *Candida spp.* pneumoniaRespiratory Distress Syndrome; *Group B Streptococcus* pneumoniaRespiratory Distress SyndromeTime of SurfactantNoAt 36 h of life, after intubationINSURE at 9 h of life; 2nd dose at 50 h of life, after intubationNoINSURE at 6 h of lifePneumothorax diagnosis (day of life)32343Site of the pneumothoraxLeftLeftRightRightLeftPneumothorax resolution (day of life)54766Extubation (day of life)54866CPAP level (cmH~2~O)44644Maximum FiO~2~0.500.700.600.500.50Maximum Silverman score66574Spontaneous respiratory rate (breaths per minute)951107511090pH, capillary blood7.227.227.297.277.29P~CO2~ (mmHg), capillary blood5864596460MAP (cmH~2~O)89888Frequency (Hz)1010101010FiO~2~0.500.500.500.500.50Amplitude, (% or cmH~2~O^a^)10010010010015^a^MAP: mean airways pressure; CPAP: continuous positive airway pressure;INSURE: INtubation-SURfactant-Extubation^a^HFOV delivered by BabyLog VN500 Fig. 1Chest X Rays of patient 1 and patient 4. Legend: patient 1: **a**: left side pneumothorax. **b**: resolution of pneumothorax 48 h later; patient 4: **c**: right side pneumothorax. **d**: resolution of pneumothorax 48 h later

Discussion and conclusion {#Sec3}
=========================

Despite an increased use of non-invasive ventilator strategies and gentle ventilation, pneumothorax remains a common complication in preterm infants. The ventilator management of infants with air leaks remains challenging in terms of both prevention and treatment. Several reports have described the successful application of high frequency ventilation (HFV) in adults with airway disruption or bronchopleural fistulae and in newborns with persistent air leaks through pneumothorax \[[@CR7], [@CR8]\]. Gonzalez et al. showed a decreased gas flow through chest tube insertion in neonates affected by pneumothorax receiving high-frequency jet ventilation with respect to those who received conventional ventilation \[[@CR7]\]. Various forms of HFV have been used to treat infants with pulmonary air leak and the superiority of this type of ventilation over conventional ventilation has been shown \[[@CR9]\]. It is not clear how HFV improves the healing of air leaks, but a ventilator strategy incorporating short inspiratory time and high respiratory rates is often effective in decreasing the magnitude of the leak \[[@CR7], [@CR8], [@CR10]\]. It is most likely that the absence of high-peak inspiratory pressures, the very short absolute inspiratory time and small tidal volume applied at higher frequencies may result in a rapid decrease of air leak, as showed by Ellsbury et al. in an animal model of pneumothorax \[[@CR11]\]. For these reasons, in the presence of gross air leak (e.g. pneumothorax), strategy should prioritise low tidal volume ventilation, more easily obtained during HFOV (1.5--2.5 ml/kg) respect to conventional mechanical ventilation (4--6 ml/kg). Management of MAP is also a critical tool and aggressive lung volume recruitment has to be avoided. MAP should be reduced where possible then maintained at a pressure sufficient to stent small airways open to avoid progression of the air leak and to guarantee sufficient oxygenation without high FiO~2~ requirements \[[@CR12]\].

Recently Kitsommart et al. \[[@CR4]\] reported 4 cases of preterm infants who developed large pneumothoraces, two of whom remaining on nasal CPAP after the diagnosis. In our experience, all the neonates developed worsening respiratory severity in terms of increasing of respiratory rate, Silverman score, FiO~2~ requirement and PCO~2~ values, making intubation mandatory. HFOV was used as first choice of treatment (not as rescue, without a chest tube) and the strategy was found successful.

Our experience reported data on the successful use of HFOV to provide conservative management of a significant pneumothorax in preterm newborns. In our opinion this approach could be used in preterm newborns developing pneumothorax while they are on nasal CPAP, remaining hemodynamically stable without clinical signs of tension pneumothorax (i.e. cyanosis, significant decline of arterial blood pressure, heart rate, respiratory rate, and SpO~2~) \[[@CR13]\] but requiring mechanical ventilation for acute worsening of the respiratory status. The suggested starting ventilator parameters in course of HFOV for pneumothorax treatment are: MAP 8--9 cm H~2~O, FiO~2~ to achieve SpO~2~ 90--95%, Respiratory Rate: 10 Hz, I:E = 1:2, ΔP: 15 cm H~2~O, eventually increased - chest to be «visibly vibrating ». This approach allowed us to avoid the increasing of air leak and the insertion of chest tube drainage and all the subsequent associated risks. However, there is no control population to which these 5 cases were compared, i.e. the pneumothorax may have resolved on their own regardless of ventilator modality. Nevertheless, considering both the reassuring outcomes observed in our babies and the risks of thoracic organ injury related to chest tube insertion because of supple chest wall, close proximity of vital structures and frail lung tissue of preterm babies, our experience could provide a starting point for novel hypothesis-testing clinical research (i.e. by comparing the conservative management of pneumothorax by HFOV or conventional mechanical ventilation in preterm infants).

Chest tube insertion for definitive drainage of a tension pneumothorax should be provided when this complication not only produces worsening of respiratory status (increase of respiratory rate, Silverman score, FiO~2~ requirement and PCO~2~ values), but also a hemodynamic instability of the patients (e.g. bradycardia, hypotension).

CPAP

:   Continuous positive airways pressure

HFOV

:   High-frequency oscillatory ventilation

HFV

:   High frequency ventilation

MAP

:   Mean airways pressure
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